迟发性药物市场规模、份额、成长分析（按疗法、按给药途径、按最终用户、按分销管道、按地区）—2025 年至 2032 年行业预测

2023 年全球迟发性药物市场规模为 36 亿美元，预计将从 2024 年的 38.8 亿美元增长到 2032 年的 70.8 亿美元，预测期内（2025-2032 年）的复合年增长率为 7.8%。

由于精神疾病盛行率的上升和 VMAT2 抑制剂治疗的进步，市场格局正在发生重大变化。加强对加速核准的监管支持正在为治疗方法的采用创造有利的环境。人们对迟发性的认识不断提高，鼓励人们积极治疗这种疾病，特别是在医疗保健基础设施不断扩大的地区。製药公司正在积极寻求策略伙伴关係，以加强其研发能力。然而，市场发展面临治疗成本高、现有治疗方法的副作用以及新兴地区的认知度低等挑战。此外，患者数量有限意味着研发投入有限，这可能会阻碍未来迟发性治疗的广泛应用。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究

迟发性治疗市场规模（依治疗类型和复合年增长率） (2025-2032)

• 市场概览
• 药品
• 外科手术

迟发性治疗市场规模（依药物类型和复合年增长率） (2025-2032)

• 市场概览
• 抗精神病药物
• VMAT2抑制剂
• 肉毒桿菌毒素
• 自然疗法
• 减少多巴胺的药物
• 其他的

迟发性药物市场规模（依给药途径及复合年增长率）（2025-2032）

• 市场概览
• 口服
• 注射

迟发性治疗药物市场规模（依最终用户和复合年增长率）（2025-2032）

• 市场概览
• 医院
• 居家护理
• 专科诊所
• 其他的

迟发性药物市场规模（依通路及复合年增长率）(2025-2032)

• 市场概览
• 医院药房
• 零售药局
• 其他的

迟发性治疗市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Neurocrine Biosciences, Inc.（US）
• Teva Pharmaceutical Industries Ltd.（Israel）
• H. Lundbeck A/S（Denmark）
• AbbVie Inc.（US）
• Otsuka Holdings Co., Ltd.（Japan）
• Astellas Pharma Inc.（Japan）
• Bausch Health Companies Inc.（Canada）
• Sumitomo Pharma America, Inc（US）
• Reviva Pharmaceuticals Holdings, Inc.（US）
• Acadia Pharmaceuticals Inc.（US）
• VANDA PHARMACEUTICALS（US）
• Eisai Co., Ltd.（Japan）
• Zydus Group（India）
• Lilly（US）
• F. Hoffmann-La Roche Ltd（Switzerland）
• Pfizer Inc.（US）
• Bristol-Myers Squibb Company（US）
• Mallinckrodt（US）

结论和建议

Global Tardive Dyskinesia Treatment Market size was valued at USD 3.6 billion in 2023 and is poised to grow from USD 3.88 billion in 2024 to USD 7.08 billion by 2032, growing at a CAGR of 7.8% during the forecast period (2025-2032).

Market insights indicate a significant shift in the tardive dyskinesia treatment landscape, driven by the rising prevalence of psychiatric disorders and advancements in VMAT2 inhibitor therapies. The heightened regulatory support for accelerated approvals is fostering a favorable environment for treatment adoption. Increased awareness of tardive dyskinesia, particularly in regions with expanding healthcare infrastructure, is encouraging proactive management of this condition. Pharmaceutical companies are actively pursuing strategic partnerships to enhance research and development efforts. However, the market faces challenges, including high treatment costs, adverse effects associated with current therapies, and limited awareness in developing areas. Additionally, constrained R&D investments due to a smaller patient population may hinder widespread adoption of tardive dyskinesia treatments in the future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Tardive Dyskinesia Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Tardive Dyskinesia Treatment Market Segments Analysis

Global Tardive Dyskinesia Treatment Market is segmented by Treatment, Drugs, Route of administration, End User, Distribution Channel and region. Based on Treatment, the market is segmented into Medication and Surgery. Based on Drugs, the market is segmented into Antipsychotics, VMAT2 Inhibitors, Botulinum Toxin, Natural Remedies, Dopamine-Depleting Medications and Others. Based on Route of administration, the market is segmented into Oral and Injectable. Based on End User, the market is segmented into Hospitals, Homecare, Specialty Clinics and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Tardive Dyskinesia Treatment Market

The global tardive dyskinesia (TD) treatment market is significantly driven by the supportive actions of regulatory bodies like the U.S. Food and Drug Administration (FDA), which have implemented expedited approval pathways for TD therapies in acknowledgment of the critical unmet medical needs. These initiatives, including fast-track designations and priority reviews, allow for a swifter market introduction of innovative treatments. This regulatory backing not only encourages pharmaceutical companies to focus their investments on developing medications for TD but also positively influences the overall outlook of the global tardive dyskinesia treatment market, fostering advancements in effective therapeutic options for patients.

Restraints in the Global Tardive Dyskinesia Treatment Market

The Global Tardive Dyskinesia Treatment market faces several constraints that hinder its growth potential. Despite the advancements brought by VMAT2 inhibitors in managing tardive dyskinesia (TD), these treatments are accompanied by adverse effects such as fatigue, depression, and somnolence, which can negatively influence patient adherence and overall quality of life. Consequently, some patients may choose to discontinue their treatment due to these side effects. Furthermore, apprehensions regarding the long-term safety profiles of these medications could lead healthcare providers to be cautious in prescribing them, ultimately slowing the widespread adoption of effective tardive dyskinesia therapies in the market.

Market Trends of the Global Tardive Dyskinesia Treatment Market

The Global Tardive Dyskinesia Treatment market is witnessing a significant trend towards advanced VMAT2 inhibitor therapies, which have transformed the therapeutic landscape for this condition. Medications like valbenazine (Ingrezza) and deutetrabenazine (Austedo) have gained prominence due to their targeted approach in addressing the underlying mechanisms of tardive dyskinesia, resulting in enhanced efficacy and safety profiles compared to traditional treatments. The introduction of innovative formulations, such as Ingrezza Sprinkle, further supports treatment adherence among patients with swallowing difficulties. As research and development in this area continue to grow, advancements in VMAT2 inhibitors are expected to drive market expansion and shape treatment paradigms in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies

Global Tardive Dyskinesia Treatment Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Medication
• Surgery

Global Tardive Dyskinesia Treatment Market Size by Drugs & CAGR (2025-2032)

• Market Overview
• Antipsychotics
• VMAT2 Inhibitors
• Botulinum Toxin
• Natural Remedies
• Dopamine-Depleting Medications
• Others

Global Tardive Dyskinesia Treatment Market Size by Route of administration & CAGR (2025-2032)

• Market Overview
• Oral
• Injectable

Global Tardive Dyskinesia Treatment Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Homecare
• Specialty Clinics
• Others

Global Tardive Dyskinesia Treatment Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Others

Global Tardive Dyskinesia Treatment Market Size & CAGR (2025-2032)

• North America (Treatment, Drugs, Route of administration, End User, Distribution Channel)
  • US
  • Canada
• Europe (Treatment, Drugs, Route of administration, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment, Drugs, Route of administration, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment, Drugs, Route of administration, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment, Drugs, Route of administration, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Neurocrine Biosciences, Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• H. Lundbeck A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Holdings Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health Companies Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sumitomo Pharma America, Inc (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Reviva Pharmaceuticals Holdings, Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acadia Pharmaceuticals Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• VANDA PHARMACEUTICALS (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Group (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lilly (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mallinckrodt (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations